Last reviewed 2026-04-20 · How we verify

Hytrin (TERAZOSIN)

Hytrin (Terazosin) is a small molecule alpha-Adrenergic Blocker that targets the Alpha-1D adrenergic receptor. Originally developed by Abbott, it was FDA approved in 1987 for the treatment of Benign Prostatic Hyperplasia and Hypertensive disorder. As an off-patent medication, Hytrin is available as a generic from multiple manufacturers. Key safety considerations include the risk of orthostatic hypotension and dizziness. Hytrin's commercial status allows for generic competition, making it a more affordable option for patients.

At a glance

Approved indications

• Benign prostatic hyperplasia
• Hypertensive disorder

Common side effects

• Asthenia
• Headache
• Back Pain
• Dizziness
• Somnolence
• Nausea
• Palpitations
• Peripheral Edema
• Weight Gain
• Postural Hypotension
• Dyspnea
• Nasal Congestion

Drug interactions

• vardenafil

Key clinical trials

• Terazosin And Metabolic Energetics in Parkinson's Disease (PHASE2)
• Terazosin for Dementia With Lewy Bodies (PHASE1,PHASE2)
• Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (EARLY_PHASE1)
• Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
• Terazosin and Parkinson's Disease Extension Study (PHASE2)
• Terazosin And Metabolic Engagement in Parkinson's Disease (PHASE1,PHASE2)
• Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (PHASE3)
• Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Hytrin CI brief — competitive landscape report
• Hytrin updates RSS · CI watch RSS